Pharmacokinetics of Darunavir/Ritonavir With Etravirine Both Twice Daily in Human Immunodeficiency Virus-Infected Adolescents and Young Adults.
Data on the combination of darunavir/ritonavir and etravirine both given twice daily in adolescents/young adults are lacking. In this study, we assessed the pharmacokinetics of darunavir/ritonavir 600/100 mg with etravirine 200 mg twice daily in 36 treatment-experienced human immunodeficiency virus-infected adolescents and young adults and found that exposures were comparable to those reported in adults.
Program for HIV Prevention and Treatment, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Thailand.
Tim R
TR
Cressey
Children's Memorial Hospital, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Ram
R
Yogev
Jacobi Medical Center, Bronx, New York.
Andrew
A
Wiznia
National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development, Maternal and Pediatric Infectious Disease Branch.
Rohan
R
Hazra
The Henry M. Jackson Foundation-Division of AIDS, a Division of The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Contractor to National Institute of Allergy and Infectious Diseases, NIH, US Department of Health and Human Services, Bethesda, Maryland.
Patrick
P
Jean-Philippe
Frontier Science & Technology, Amherst, New York.
Bobbie
B
Graham
Frontier Science & Technology, Amherst, New York.
Amy
A
Gonzalez
Harvard School of Public Health, Boston, Massachusetts.
Paula
P
Britto
Harvard School of Public Health, Boston, Massachusetts.
Vincent J
VJ
Carey
University of Nebraska Medical Center, Omaha.
Courtney V
CV
Fletcher
University of Alabama at Birmingham.
Edward P
EP
Acosta
D000293:Adolescent; D000069454:Darunavir / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004338:Drug Combinations; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009570:Nitriles; D011724:Pyridazines / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D011743:Pyrimidines; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D019438:Ritonavir / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D019562:Viral Load / Q000187:drug effects; D055815:Young Adult
D004338:Drug Combinations; D017320:HIV Protease Inhibitors; D009570:Nitriles; D011724:Pyridazines; D011743:Pyrimidines; D018894:Reverse Transcriptase Inhibitors; C451734:etravirine; D019438:Ritonavir; D000069454:Darunavir
antiretrovirals; darunavir; etravirine; pediatrics; ritonavir